vs
MIMEDX GROUP, INC.（MDXG）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是MIMEDX GROUP, INC.的1.6倍（$188.3M vs $118.1M），BRC Group Holdings, Inc.净利率更高（47.9% vs 12.9%，领先35.1%），MIMEDX GROUP, INC.同比增速更快（27.1% vs -21.9%），过去两年MIMEDX GROUP, INC.的营收复合增速更高（18.1% vs -15.4%）
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
MDXG vs RILY — 直观对比
营收规模更大
RILY
是对方的1.6倍
$118.1M
营收增速更快
MDXG
高出49.0%
-21.9%
净利率更高
RILY
高出35.1%
12.9%
两年增速更快
MDXG
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.1M | $188.3M |
| 净利润 | $15.2M | $90.3M |
| 毛利率 | 83.9% | 79.5% |
| 营业利润率 | 17.8% | 32.3% |
| 净利率 | 12.9% | 47.9% |
| 营收同比 | 27.1% | -21.9% |
| 净利润同比 | 104.2% | 1710.8% |
| 每股收益（稀释后） | $0.10 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDXGRILY
| Q4 25 | $118.1M | $188.3M | ||
| Q3 25 | $113.7M | $215.3M | ||
| Q2 25 | $98.6M | $188.2M | ||
| Q1 25 | $88.2M | $197.2M | ||
| Q4 24 | $92.9M | $241.0M | ||
| Q3 24 | $84.1M | $225.5M | ||
| Q2 24 | $87.2M | $256.0M | ||
| Q1 24 | $84.7M | $263.4M |
净利润MDXGRILY
| Q4 25 | $15.2M | $90.3M | ||
| Q3 25 | $16.7M | $91.1M | ||
| Q2 25 | $9.6M | $139.5M | ||
| Q1 25 | $7.0M | $-10.0M | ||
| Q4 24 | $7.4M | $-5.6M | ||
| Q3 24 | $8.1M | $-284.4M | ||
| Q2 24 | $17.6M | $-433.6M | ||
| Q1 24 | $9.3M | $-49.2M |
毛利率MDXGRILY
| Q4 25 | 83.9% | 79.5% | ||
| Q3 25 | 83.5% | 83.7% | ||
| Q2 25 | 81.1% | 81.3% | ||
| Q1 25 | 81.2% | 81.4% | ||
| Q4 24 | 81.8% | 79.8% | ||
| Q3 24 | 81.8% | 82.1% | ||
| Q2 24 | 83.0% | 84.5% | ||
| Q1 24 | 84.7% | 85.3% |
营业利润率MDXGRILY
| Q4 25 | 17.8% | 32.3% | ||
| Q3 25 | 19.5% | 30.4% | ||
| Q2 25 | 12.5% | 5.7% | ||
| Q1 25 | 9.4% | -31.2% | ||
| Q4 24 | 11.9% | -69.2% | ||
| Q3 24 | 13.3% | -36.4% | ||
| Q2 24 | 26.9% | -90.8% | ||
| Q1 24 | 15.6% | -6.1% |
净利率MDXGRILY
| Q4 25 | 12.9% | 47.9% | ||
| Q3 25 | 14.7% | 42.3% | ||
| Q2 25 | 9.8% | 74.1% | ||
| Q1 25 | 8.0% | -5.1% | ||
| Q4 24 | 8.0% | -2.3% | ||
| Q3 24 | 9.6% | -126.1% | ||
| Q2 24 | 20.2% | -169.4% | ||
| Q1 24 | 10.9% | -18.7% |
每股收益（稀释后）MDXGRILY
| Q4 25 | $0.10 | $2.78 | ||
| Q3 25 | $0.11 | $2.91 | ||
| Q2 25 | $0.06 | $4.50 | ||
| Q1 25 | $0.05 | $-0.39 | ||
| Q4 24 | $0.05 | $-0.01 | ||
| Q3 24 | $0.05 | $-9.39 | ||
| Q2 24 | $0.12 | $-14.35 | ||
| Q1 24 | $0.06 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $166.1M | $226.6M |
| 总债务越低越好 | $18.0M | $1.4B |
| 股东权益账面价值 | $256.5M | $-171.5M |
| 总资产 | $342.7M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MDXGRILY
| Q4 25 | $166.1M | $226.6M | ||
| Q3 25 | $142.1M | $184.2M | ||
| Q2 25 | $118.9M | $267.4M | ||
| Q1 25 | $106.4M | $138.3M | ||
| Q4 24 | $104.4M | $146.9M | ||
| Q3 24 | $88.8M | $159.2M | ||
| Q2 24 | $69.0M | $236.9M | ||
| Q1 24 | $48.5M | $190.7M |
总债务MDXGRILY
| Q4 25 | $18.0M | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $19.0M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MDXGRILY
| Q4 25 | $256.5M | $-171.5M | ||
| Q3 25 | $238.9M | $-260.5M | ||
| Q2 25 | $216.6M | $-351.7M | ||
| Q1 25 | $202.8M | $-496.8M | ||
| Q4 24 | $193.1M | $-488.2M | ||
| Q3 24 | $181.0M | $-497.6M | ||
| Q2 24 | $168.0M | $-218.3M | ||
| Q1 24 | $155.7M | $228.4M |
总资产MDXGRILY
| Q4 25 | $342.7M | $1.7B | ||
| Q3 25 | $319.0M | $1.7B | ||
| Q2 25 | $291.1M | $1.5B | ||
| Q1 25 | $270.4M | $1.5B | ||
| Q4 24 | $263.9M | $1.8B | ||
| Q3 24 | $243.9M | $2.2B | ||
| Q2 24 | $230.2M | $3.2B | ||
| Q1 24 | $221.7M | $5.0B |
负债/权益比MDXGRILY
| Q4 25 | 0.07× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.0M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.64× | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDXGRILY
| Q4 25 | $25.0M | $26.2M | ||
| Q3 25 | $29.3M | $-60.6M | ||
| Q2 25 | $14.4M | $-25.6M | ||
| Q1 25 | $5.3M | $184.0K | ||
| Q4 24 | $18.8M | $-2.7M | ||
| Q3 24 | $19.6M | $19.5M | ||
| Q2 24 | $21.8M | $111.5M | ||
| Q1 24 | $6.0M | $135.4M |
现金转化率MDXGRILY
| Q4 25 | 1.64× | 0.29× | ||
| Q3 25 | 1.75× | -0.66× | ||
| Q2 25 | 1.50× | -0.18× | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 2.53× | — | ||
| Q3 24 | 2.42× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
